Physician profile
Robert E Marsico
NPI 1952304560
$9,879.16
in general payments reported to CMS, 2019-2025
27 companies · $530 in 2025
The $530 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,906 · 2020: $1,046 · 2021: $748 · 2022: $1,964 · 2023: $1,910 · 2024: $775 · 2025: $530.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,215.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,215.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,564.62 | 2019-2024 | |
| Genzyme Corporation | $775.94 | 2019-2023 | |
| Leo Pharma INC. | $609.56 | 2022-2025 | Adbry, Anzupgo |
| Galderma Laboratories, L.P. | $607.66 | 2019-2024 | |
| Incyte Corporation | $548.26 | 2021-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $546.01 | 2019-2023 | Dupixent, Libtayo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $438.96 | 2022-2024 | Spevigo |
| Dermavant Sciences, INC. | $422.80 | 2023-2024 | Vtama |
| Novartis Pharmaceuticals Corporation | $402.68 | 2019-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $390.52 | 2019-2023 | Targretin |
| Sun Pharmaceutical Industries INC. | $319.79 | 2020-2023 | Winlevi, Absorica Ld |
| E.R. Squibb & Sons, L.L.C. | $307.75 | 2022-2023 | Sotyktu |
| Ucb, INC. | $272.12 | 2019-2023 | Bimzelx |
| Lilly USA, LLC | $249.24 | 2019-2022 | |
| Janssen Scientific Affairs, LLC | $243.70 | 2020-2025 | Tremfya |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $230.24 | 2023-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Amgen INC. | $199.24 | 2020-2023 | Otezla, Enbrel |
| Pfizer INC. | $186.53 | 2019-2022 | |
| Almirall LLC | $126.70 | 2019 | |
| Journey Medical Corporation | $124.99 | 2021 | |
| Krystal Biotech INC | $114.05 | 2023 | Vyjuvek |
| Regeneron Pharmaceuticals, INC. | $75.51 | 2025 | Dupixent |
| Dermira, INC. | $41.26 | 2019-2021 | |
| Vyne Pharmaceuticals INC. | $25.28 | 2020 | |
| Mayne Pharma Commercial LLC | $21.38 | 2023 | |
| Epi Health, LLC | $18.61 | 2019 | |
| Janssen Biotech, INC. | $15.76 | 2023 | Stelara |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Marsico listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.